dismiss

Our Clean Sweep Live Auction is coming up fast! Next Tuesday, September 26th at 9:30AM EST

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

Forward Printable StoryPrint Comment

 

More HCB News

Radiation shielding in the era of patient satisfaction Making shielded environments less intimidating and more conducive to workflow

ASTRO Exhibitors A few of the companies you'll want to visit with in the ASTRO exhibit hall

ASTRO Product Showcase Some of the products and services on display at ASTRO 2017

Montreal Heart Institute acquires da Vinci Xi for cardiac surgery in Canada Innovation for mitral valve and coronary artery bypass cardiac surgery

Penn Medicine treats first patient with Varian Halcyon radiation treatment platform Cuts down on time and costs

Third tricuspid valve stent implanted successfully in Italy Ministry of Health allowed the implant as a last resort for the patient

New study pinpoints most effective infection control practices Maintain a sterile operating field and track outcomes

Cardiologist salaries are on the rise in the U.S., survey finds Growing faster on the private side

International Atomic Energy Agency in partnership to get new Varian linac Will help the agency answer requests for standards and guidance

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

Seno Medical Instruments Announces Pilot Study Data of Imagio® Breast Imaging System at RSNA 2015 Annual Meeting

Press releases may be edited for formatting or style
SAN ANTONIO, Dec. 21, 2015 /PRNewswire/ -- Seno Medical Instruments, Inc., the company pioneering the development of an opto-acoustic (OA) device as a new tool to improve the process of diagnosing breast cancer, announced results of its Pilot Study portion of the PIONEER pivotal study. The pilot study demonstrated the potential of the company's Imagio breast imaging system to improve physicians' ability to accurately classify benign breast masses compared to traditional ultrasound methods. The results of the 100 subject pilot study, conducted as the initial part of a larger U.S.-based, multicenter PIONEER pivotal study of over 2,000 subjects, were presented at the annual meeting of the Radiological Society of North America (RSNA) on December 2 in Chicago, IL.

The PIONEER study is being conducted to demonstrate the ability of the Imagio OA breast imaging system to downgrade BI-RADS® (Breast Imaging-Reporting and Data System) scores. Specifically, whether masses originally scored BI-RADS (BR) 4a or 4b (in which a suspicious abnormality is discovered and a biopsy is recommended) could be downgraded to either BR 3 (probably benign, <2% likelihood of malignancy with short-interval follow-up recommended) or 2 (benign) and if masses coded BR 3 could be downgraded to 2.

Story Continues Below Advertisement

Introducing HALCYON

We set out to rethink the way we approached radiotherapy, so you can redefine the way you fight cancer. Visit us at ASTRO booth #717. Click above to learn more



Seven independent breast radiologist readers (IRs) and an expert radiologist (ER) trainer blindly assessed 102 masses from the pilot study cases using only Imagio OA images. Among these subjects, there were 75 biopsied masses (39 benign, 36 malignant). Gray-scale ultrasound images were taken with the Imagio system's conventional ultrasound immediately prior to the OA exam. These images were designated the internal ultrasound control (IUC). Later, the IRs assigned a BR score to these images.

Using OA, the IRs downgraded conventional diagnostic ultrasound findings classified BR 3 masses to BR 2 in 33% of cases, BR 4a masses to BR 2 or 3 in 53% of cases, and BR 4b masses to BR 3 or 2 in 33% of cases. Using OA, the IRs downgraded BI-RADS categories of the internal ultrasound control-classified BR 3 masses to BR 2 in 43% of cases, BR 4a to either BR 3 or 2 in 43% of cases and BR 4b masses to either BR 3 or 2 in 13% of cases. OA had 97.6% sensitivity and 44.4% specificity.

"Downgrading benign masses classified as BR 4b (moderate suspicion), 4a (low suspicion) and 3 without missing cancers is an unmet need that the Imagio OA breast imaging system can potentially help address," said Erin Neuschler, MD, Northwestern Medicine Radiologist, Assistant Professor of Radiology at the Northwestern University Feinberg School of Medicine and the Co-Principal Investigator of the PIONEER Study. "If these pilot findings are verified after the completion of the multicenter PIONEER Study, we will have confirmation that the Imagio OA breast imaging system could help women not only avoid biopsy procedures but also multiple short interval follow-up ultrasound exams over two years."
  Pages: 1 - 2 - 3 >>

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED